公开(公告)号：US20210206818A1

公开(公告)日：2021-07-08

申请号：US16071131

申请日：2017-01-20

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun HUANG ,  Joshua P. FREDERICK ,  Kristine MCKINNEY ,  Christina HENDERSON ,  Kahlin CHEUNG-ONG ,  Joseph BOLEN ,  Stephen Michael KELSEY ,  Michael MORIN ,  Sushma GURUMURTHY ,  Kerry BENENATO ,  Stephen HOGE ,  Iain MCFADYEN ,  Vladimir PRESNYAK

IPC: C07K14/47 ,  A61K9/51 ,  A61P35/00

Abstract: The invention features isolated mRNAs encoding at least one intracellular binding domain, including mRNAs comprising one or more modified nucleobase and preferably lacking an encoded scaffold polypeptide, and methods of using the same, for example, for inducing apoptosis and/or treating cancer (e.g., liver cancer or colorectal cancer).

公开(公告)号：US20190175727A1

公开(公告)日：2019-06-13

申请号：US16279372

申请日：2019-02-19

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun HUANG ,  Sze-Wah TSE ,  Jared IACOVELLI ,  Kristine MCKINNEY ,  Nicholas VALIANTE

IPC: A61K39/39 ,  C07K14/725 ,  A61K9/50 ,  A61P35/00

Abstract: The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.

公开(公告)号：US20180311343A1

公开(公告)日：2018-11-01

申请号：US15995519

申请日：2018-06-01

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun HUANG ,  Sze-Wah TSE ,  Jared IACOVELLI ,  Kristine MCKINNEY ,  Kristen HOPSON

IPC: A61K39/39 ,  A61P35/00 ,  A61K39/00 ,  A61K9/51 ,  C07K14/47 ,  A61K39/12 ,  C12N7/00 ,  A61K39/02

CPC classification number: A61K31/7088 ,  A61K39/39 ,  A61K2039/53

Abstract: The disclosure features isolated mRNAs encoding a polypeptide that enhances immune responses to an antigen(s) of interest, such as polypeptides that activate Type I interferon pathway signaling or NFkB signaling, including mRNAs comprising one or more modified nucleobase. The disclosure also features methods of using the same, for example, for enhancing immune responses when administered with an antigen(s) of interest, such as to stimulate anti-cancer immune responses or anti-pathogen immune responses.

公开(公告)号：US20210128721A1

公开(公告)日：2021-05-06

申请号：US16951092

申请日：2020-11-18

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun HUANG ,  Sze-Wah TSE ,  Jared IACOVELLI ,  Kristine MCKINNEY ,  Nicholas VALIANTE

IPC: A61K39/39 ,  A61K39/00 ,  A61K9/00 ,  A61K9/51 ,  A61P35/00 ,  A61K9/50 ,  C07K14/725

Abstract: The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.

公开(公告)号：US20190351039A1

公开(公告)日：2019-11-21

申请号：US16482473

申请日：2018-02-01

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun HUANG ,  Sze-Wah TSE ,  Jared IACOVELLI ,  Kristine MCKINNEY ,  Nicholas VALIANTE

IPC: A61K39/00 ,  A61K9/50 ,  A61K39/39 ,  A61K9/51 ,  A61K9/00

Abstract: The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.

公开(公告)号：US20200261572A1

公开(公告)日：2020-08-20

申请号：US16671921

申请日：2019-11-01

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun HUANG ,  Sze-Wah TSE ,  Jared IACOVELLI ,  Kristine MCKINNEY ,  Kristen HOPSON

IPC: A61K39/39 ,  A61K31/7088 ,  A61P35/00 ,  A61K39/00 ,  A61K39/02 ,  C12N7/00 ,  A61K39/12 ,  C07K14/47 ,  A61K9/51

Abstract: The disclosure features isolated mRNAs encoding a polypeptide that enhances immune responses to an antigen(s) of interest, such as polypeptides that activate Type I interferon pathway signaling or NFkB signaling, including mRNAs comprising one or more modified nucleobase. The disclosure also features methods of using the same, for example, for enhancing immune responses when administered with an antigen(s) of interest, such as to stimulate anti-cancer immune responses or anti-pathogen immune responses.

公开(公告)号：US20190119357A1

公开(公告)日：2019-04-25

申请号：US15743112

申请日：2016-07-22

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-chun HUANG ,  Josh FREDERICK ,  Kristine MCKINNEY ,  Christina HENDERSON ,  Kahlin CHEUNG-ONG ,  Joseph BOLEN ,  Stephen Michael KELSEY ,  Michael MORIN ,  Sushma GURUMURTHY

IPC: C07K14/81 ,  C07K14/47 ,  A61K9/127 ,  A61K47/69 ,  A61P35/00 ,  A61P35/02 ,  A61K9/00 ,  A61K9/51 ,  C07K16/28 ,  A61K39/395 ,  A61K38/57 ,  A61K38/17

Abstract: The invention features isolated mRNAs encoding fusion polypeptides comprising a Stefm A (SteA) scaffold polypeptide and one or more binding polypeptides, such as one or more Bc1-2 homology 3 (BH3) domains, including mRNAs comprising one or more modified nucleobase, and methods of using the same, for example, for inducing apoptosis and/or treating cancer (e.g., liver cancer or colorectal cancer).

公开(公告)号：US20170210788A1

公开(公告)日：2017-07-27

申请号：US15328187

申请日：2015-07-23

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun HUANG ,  Josh FREDERICK ,  Kristine MCKINNEY ,  Christina HENDERSON

IPC: C07K16/18 ,  A61K48/00 ,  C07K14/79 ,  A61K9/16 ,  C07K14/78 ,  C07K14/81

CPC classification number: C07K16/18 ,  A61K9/1617 ,  A61K48/0066 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/78 ,  C07K14/79 ,  C07K14/8114 ,  C07K14/8139 ,  C07K16/00 ,  C07K16/082 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/76 ,  C07K2317/80 ,  C07K2317/94 ,  C07K2318/20 ,  C07K2319/70 ,  C12N15/87

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modified polynucleotides comprising at least one intrabody construct.